Drugs / Asunercept
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02853565 | Aug 2016 → Sep 2018 | glioblastoma | CANbridge Life Sciences Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01736436 | Jan 2013 → Dec 2015 | myelodysplastic syndrome | Apogenix GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03158389 | May 2018 → Feb 2023 | adult glioblastoma | University Hospital Heidelberg | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05447195 | Oct 2021 → Jan 2024 | glioblastoma | CANbridge Life Sciences Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04535674 | Oct 2020 → Oct 2021 | COVID-19, viral pneumonia | Apogenix GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03746288 | Nov 2018 → Jul 2021 | glioblastoma | CANbridge Life Sciences Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01071837 | Dec 2009 → Oct 2014 | glioblastoma | Apogenix GmbH | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04351724 | Apr 2020 → Dec 2021 | COVID-19 | Medical University of Vienna | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05639192 | Nov 2022 → Aug 2023 | COVID-19 | Apogenix GmbH | Terminated | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | asunercept | “Asunercept (company code APG101 [Apogenix AG]; company code CAN008 [CANbridge Pharmaceuticals]) is a novel glycosylated fusion protein that has shown promising effectiveness in...” PMID 34911992 ↗ Dec 2021 |
| Known as | APG101 | “an investigational drug (APG101; International Nonproprietary Name: asunercept)” NCT04535674 ↗4“Asunercept (APG101) will be administered once per week as an i.v. infusion” NCT05639192 ↗ |
| Known as | Apocept | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297886 ↗ |
| Known as | Asinercept | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297886 ↗ |
| Known as | CAN008 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03746288 ↗ |
| Action | Inhibit | “The target of CAN008 is the inhibition of CD95L.” NCT02853565 ↗ |
| Modality | Protein / enzyme biologic | “APG101 is a fusion protein” NCT01071837 ↗ |
| Route | Intravenous | “100 mg APG101 intravenous weekly” NCT01736436 ↗ |
| Target | FASLG | “Tumor necrosis factor ligand superfamily member 6 binding agent” CHEMBL4297886 ↗ |